ArticleBMC psychiatry2025
Prevalence and associated factors of antipsychotic-induced extrapyramidal symptoms in the Tigray region.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtrapyramidal symptoms affect an average of 37%, with a maximum prevalence of 71.4%, among individuals on antipsychotics. About one in five patients experiences Parkinsonism, and more than one in ten experiences akathisia. These symptoms can significantly increase relapse rates, elevate healthcare costs (approximately $27,408), and contribute to stigmatization. In Tigray, where antipsychotic use is rising, data on Extrapyramidal symptoms are limited. This study aimed to fill this research gap to better patient care and management.
objectivesThe aim of this study was to determine the prevalence of Extrapyramidal symptoms associated with antipsychotic medications. Additionally, it sought to identify factors contributing to these side effects among patients.
methodsThis study was conducted across five public hospitals in the Tigray region, utilizing a comprehensive approach that included face-to-face interviews, direct observations, card reviews, and physical examinations. A total of 834 participants were selected through a multistage sampling technique to ensure representativeness, using the Extra Pyramidal Symptom Rating Scale (ESRS) for standardized evaluation. Data collected were analyzed using SPSS version 27.
resultThe study findings showed that the prevalence rates of Parkinsonism, Akathisia, Dystonia, and Tardive Dyskinesia were 9.9%, 6.9%, 5.0%, and 2.4%, respectively. The multivariate analysis revealed several common risk factors associated with these extrapyramidal symptoms. Both Parkinsonism and Akathisia were significantly associated with various factors, including the type of antipsychotic medication, illness relapse, comorbid medical conditions, anticholinergic medication, perceived stigma, and current khat use. Additionally, Parkinsonism was associated with the type of mental illness. Dystonia was also associated with marital status, anticholinergic medication, perceived stigma, and tobacco use. Lastly, Tardive Dyskinesia was associated with educational status and medication adherence. CONCLUSION AND RECOMMENDATIONS: Although Extrapyramidal symptoms were reported at lower rates than in previous studies, psychiatry professionals should routinely screen for EPS and tailor treatment to patient-specific factors. Efforts to reduce stigma around these side effects are also essential to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.